Clinical efficacy of umifenovir in acute respiratory viral infections


Ponezheva Zh.B., Ponezheva L.O., Kupchenko A.N., Gultyaev M.M.

1 Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2 I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Moscow, Russia; 3 A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
Objective. To evaluate the clinical efficacy of umifenovir in acute respiratory viral infections (ARVI) in adult patients.
Subjects and methods. The investigation covered 47 patients aged 18 to 60 years with ARVI, of them there were 26 (55.3%) men and 21 (44.7%) women. 53.2% of the patients were aged 18 to 30 years. According to the timing of their search for medical care and their treatment, the patients were divided into 2 groups: 1) 23 patients who started receiving treatment during the first 48 hours after onset of symptoms; 2) 24 patients sought medical advice at 2–3 days of the disease. All the patients received 2 umifenovir capsules 4 times daily for 5 days. To verify the diagnosis, the investigators applied a rapid influenza diagnostic technique by an immunochromatographic test using the Influenza A + B test system («Vegal Farmaceutica S.L.», Spain), a PCR assay for detecting the viruses of influenza and ARVI (nasopharyngeal swabs), as well as comprehensive examination including clinical blood analysis, general urinalysis, chest radiography, and electrocardiography (if necessary). Phagocytic activity of monocytes and granulocytes, IFN-like activity of serum and supernatant fluid of cultured blood cells incubated in the medium with addition of phytohemagglutinin (PHA) or Newcastle disease virus, or without them (interferon status) were studied over time.
Results. A clinical effect is noted in the treatment of catarrhal respiratory syndrome, in the reduction of the febrile period, and more rapid recovery in Group 1.
Conclusion. Early treatment can considerably shorten the duration of the disease and reduce its major symptoms and the risk of complications.
Keywords: umifenovir, interferons, influenza, acute respiratory viral infections
Read entire article

Literature

  1. WHO. WHORISKASSESSMENT. Human infections with avian influenza A(H7N9) virus. http://www.who.int/influenza/gisrs_laboratory/ en/
  2. [Records of Federal center of Hygiene and Epidemiology of Rospotrebnadzor]. Мoscow, 2016. (In Russ.). http://www.garant.ru/products/ipo/prime/ doc/71074878/# http://rospotrebnadzor.ru/rss_all/-/asset_publisher/Kq6J/content/id/146831
  3. Sel’kova E.P., Kalyuzhin O.V. [SARS and influenza. To help a practicing doctor]. Мoscow: Meditsinskoe informatsionnoe agentstvo, 2015. 224 p. (In Russ.).
  4. Ponezheva Zh.B., Kupchenko А.N. [Influenza and immunization]. Infektsionnye Bolezni 2016; 14(4): 71–80. (In Russ.).
  5. [Guidelines for the diagnosis and treatment of influenza]. Мoscow, 2016. (In Russ.). https://petrsu.ru/files/user/fdbd9903df09bb6f04f397450 a13732b/ Recom_ Flu.pdf
  6. van de Sandt C.E., Kreijtz J.H.C.M., Rimmelzwaan G.F. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses 2012; 4(9): 1438–76. DOI: 10.3390/v4091438.
  7. Burtseva E.I., Shevchenko E.S., Belyakova N.V., Oskerko T.А., Merkulova L.N., Kolobukhina L.V., Vartanyan R.N., Prilipov А.G., Rotan M., Zaplatnikov А.L. [Monitoring of the sensitivity of the isolated in Russia epidemic strains of influenza viruses to specific chemotherapy drugs] Voprosy Virusologii 2009; (2): 24–8. (In Russ.).
  8. Kalyuzhin О.V. [Acute respiratory viral infections: current challenges, antiviral response, immunoprophylaxis and immunotherapy]. Мoscow: Meditsinskoe informatsionnoe agentstvo, 2014. 144 p. (In Russ.).
  9. Glushkov R.G., Fadeeva N.I., Leneva I.A. [Molecular biological features of the action of Arbidol – new antiviral drug]. Khimiko-farmatsevticheskij zhurnal 1992; (2): 8–15. (In Russ.).
  10. Nicholson K.G., Webster R.G., Hay A.J. Human Influenza. Textbook of Influenza. Blackwell Science (United Kingdom), 1998; 219–66.
  11. Leneva I.A., Russell R.J., Boriskin Y.S., Hay A.J. Characteristics of Arbidol – Resistant Mutants of Influenza Virus: Implications for the Mechanism of Anti–Influenza Action of Arbidol. Antiviral Res. 2009; 81: 132–40.
  12. Teissier E., Zandomeneghi G., Loquet A., Lavillette D., Lavergne J.P., Montserret R., Cosset F.L., Bockmann A., Meier B.H., Penin F., Pecheur E.I. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 2011; 6(1): e15874. DOI: 10.1371/journal. pone.0015874
  13. Leneva I.А., Fedyakina I.T., Eropkin M.YU., Gudova N.V., Romanovskaya А.А., Danilenko D.M., Vinogradova S.M., Lepeshkin А.YU., Shestopalov А.M. [The study of the antiviral activity of domestic anti-influenza chemotherapy in cell culture and in animal models]. Voprosy Virusologii 2010; (3): 19–27. (In Russ.).
  14. Grigoryan S.S., Majorov I.А., Ivanova А.M., Ershov F.I. [Assessment interferon status of people in the sample of whole]. Voprosy Virusologii 1988; 33(4): 433–6. (In Russ.).
  15. Kupchenko A.N., Ponezheva Z.B., Romeyko V.B. [Clinical efficacy of standard antiviral drugs in the treatment of ARVI patients with complications]. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2016; (6): 48–51. (In Russ.).
  16. Shipilov M.V. [Pathogenetic and prognostic significance of the interferon (γ and α) in acute respiratory viral infections]. Vrach-aspirant 2011; 48(5): 92–8. (In Russ.).
  17. Kiselev O.I., Maleev V.V., Deeva EH.G., Leneva I.А., Sel’kova E.P., Osipova E.А., Obukhov А.А., Nadorov S.А., Kulikova E.V. [The clinical efficacy of the drug Arbidol (umifenovir) in the treatment of influenza in adults: interim results of a multicenter double-blind, randomized, placebo-controlled trial ARBITR]. Terapevticheskij Аrkhiv 2015; (1): 88–96. (In Russ.).


About the Autors

For correspondence:
Zhanna B. Ponezheva, MD; Leading Researcher, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Address: 15, Eighth Sokolinaya Gora St., Build. 2, Moscow 105275, Russia
Telephone: +7(495) 365-00-18
E-mail: doktorim@mail.ru
Information about the authors:
Liana O. Ponezheva, Postgraduate Student, Department of Allergology and Clinical Immunology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Moscow, Russia; e-mail: ponejevaliana@gmail.com
Аleksandra N. Kupchenko, Junior Researcher, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; e-mail: crie@pcr.ru
Maksim M. Gultyaev, Cand. Med. Sci., Senior Researcher, Laboratory of Immunopathogenesis, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia; e-mail:


Similar Articles

Back to Content

Бионика Медиа